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Do inflammatory cytokine genes 
confer susceptibility to diabetic 
nephropathy?
Shiro Maeda1
Microinflammation has been recognized as an important process for 
the progression of diabetic nephropathy. Inflammatory cytokines, 
such as interleukin-6 produced by infiltrating cells or renal cells, 
play important roles in the pathogenesis of diabetic nephropathy. 
Although the mechanisms underlying the regulation of these 
cytokines in the kidneys of patients with diabetes mellitus remain 
unclear, genetic variations in the genes encoding the inflammatory 
cytokines might confer susceptibility to the disease by altering their 
functions or expressions.
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Genetic susceptibility plays an important 
role in the pathogenesis of diabetic neph-
ropathy. Efforts, including the genome-
wide association study (GWAS), have 
been invested worldwide to identify the 
susceptibility gene for diabetic neph-
ropathy. GWAS is considered a power-
ful and promising approach; however, to 
date, it has not completely covered the 
human genome. Thus, the candidate gene 
approach, along with an appropriate analy-
sis, continues to be the method of choice 
to evaluate the contribution of the genes 
of interest in conferring susceptibility to 
the disease. Ng et al.1 (this issue) have now 
reported the association of the interleukin 
(IL)-6 gene with reduced glomerular filtra-
tion rate in patients with type 2 diabetes; 
their approach is a good example of evalu-
ating the association of a gene with disease 
susceptibility. I will discuss whether the 
inflammatory cytokine gene IL-6 is a sus-
ceptibility gene for diabetic nephropathy.
Role of inflammatory cytokines in the 
pathogenesis of diabetic nephropathy
Traditionally, chronic alterations in 
metabolic and/or hemodynamic factors 
have been recognized as the main causes 
of renal injury in patients with diabetes 
mellitus. In recent years, these conven-
tional mechanisms have been considered 
only partially responsible for the devel-
opment and/or progression of the dis-
ease. Further, several other factors, such 
as the activity of reactive oxygen species 
or various inflammatory processes, have 
been shown to play important roles in the 
pathogenesis of diabetic nephropathy; 
these factors are not completely inde-
pendent but interact with each other.
For many years, diabetic nephropathy 
was believed to be a noninflammatory 
disease, although inflammatory-cell 
infiltration was observed in the kidneys 
of some patients with diabetes mellitus. 
Furuta et al. reported a considerable 
amount of macrophage infiltration in 
the kidney that was moderately affected 
with diabetic nephropathy.2 Another 
group of researchers observed mac-
rophage infiltration not only in the 
glomeruli but also in the interstitium 
of the kidneys of patients with diabetic 
nephropathy.3 Most researchers did 
not focus enough on the increase in 
the number of inflammatory cells in a 
diabetic kidney, probably because the 
degree of infiltration in a diabetic kidney 
was lower than that observed in prolif-
erative glomerulo nephritis. Recently, 
low-grade or subclinical inflammation, 
termed microinflammation, has been 
shown to play an important role in the 
pathogenesis of atherosclerosis and also 
in microvascular diseases. In addition, 
it has been shown that suppression of 
macrophage infiltration by radiation4 or 
by the use of immuno suppressive agents5 
could ameliorate the development and/or 
progression of diabetic glomerular injury 
in experimental diabetes mellitus. On the 
basis of all these observations, we specu-
late that inflammatory processes contrib-
ute to the development and progression 
of diabetic nephropathy.
The first step of macrophage infiltra-
tion is the attachment of mononuclear 
leukocytes to vascular endothelial cells. 
This attachment is regulated by adhesion 
molecules such as intercellular adhe-
sion molecule-1 (ICAM-1), E-selectin, 
and P-selectin, or by chemokines such 
as monocyte chemotactic protein-1 
(MCP-1). The expressions of ICAM-1, 
E-selectin, and P-selectin were increased 
in the kidneys of patients with diabetic 
nephropathy3 and in the kidneys of rats 
with streptozotocin-induced diabetes. 
Interestingly, Okada et al. have dem-
onstrated that ICAM-1 knockout mice 
were protected from the progression 
of albuminuria, glomerular hypertro-
phy, and interstitial fibrosis at 6 months 
after the induction of diabetes mellitus, 
whereas no difference was observed in 
the pathological degree of albuminuria 
between ICAM-1-null mice and wild-
type mice at 1 month after the injection 
of streptozotocin.6 These results suggest 
that the microinflammation observed in 
the diabetic kidney possibly contributes 
to the progression of the disease rather 
than its onset.
Inflammatory cytokines such as IL-1, 
IL-6, and IL-18, which are produced by the 
infiltrating macrophages, might contribute 
to the progression of renal injury either 
directly or indirectly. Further, increased 
expression of these cytokines has been 
reported in the kidneys of patients with 
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diabetes mellitus7 or experimental diabe-
tes mellitus.8 The increase in the systemic 
and/or tissue expressions of these cytokines 
was reported to correlate with the severity 
of diabetic nephropathy or with urinary 
albumin excretion. These findings support 
the contribution of microinflammation to 
the progression of diabetic nephropathy, 
although precise mechanisms underlying 
the process of microinflammation and its 
contribution to the progression of renal 
injury remain to be elucidated.
Genetics of diabetic nephropathy
On the basis of cumulative evidence, it 
is suggested that genetic susceptibility 
plays an important role in the pathogen-
esis of diabetic nephropathy. Krolewski 
et al. reported that cumulative incidence 
of diabetic retinopathy increased lin-
early with increasing duration of diabe-
tes, but the occurrence of nephropathy 
was extremely rare at 20–25 years after 
the onset of diabetes, and only a mod-
est number of individuals with diabetes 
(~30%) developed diabetic nephropathy.9 
Familial clustering of diabetic nephropa-
thy was also reported in both type 1 and 
type 2 diabetes, strongly suggesting the 
association of genetic factors with diabetic 
nephropathy. To date, extensive research 
has been performed to identify the sus-
ceptibility gene for diabetic nephropathy. 
Several candidate genes, such as those for 
the renin–angiotensin system, have been 
shown to be associated with susceptibility 
to the disease in several independent 
cohorts. However, most genes responsible 
for conferring susceptibility to diabetic 
nephropathy remain unidentified thus far 
(Figure 1). Recently, GWASs on several 
common diseases, such as type 2 diabe-
tes, were conducted, and these analyses 
successfully identified convincing candi-
date genes for the diseases. With regard 
to diabetic nephropathy, we genotyped 
more than 80,000 single-nucleotide poly-
morphism (SNP) loci and consequently 
identified solute carrier gene family 12 
member 3 (SLC12A3),10 engulfment 
and cell motility 1 (ELMO1),11 and 
neurocalcin-δ (NCALD)12 as novel candi-
dates for susceptibility genes for diabetic 
nephropathy. However, further replica-
tion studies are required to validate the 
effects of these genes.
Association of inflammatory cytokine 
genes with susceptibility to diabetic 
nephropathy
As mentioned above, inflammatory 
cytokine genes might be candidate genes 
for conferring susceptibility to dia-
betic nephropathy; several genes, such 
as IL-1, IL-6, IL-18, and MCP-1, have 
been examined in this regard thus far. 
Ng et al. 1 (this issue) report the asso-
ciation of a haplotype of the IL-6 gene 
with reduced renal function in diabetic 
nephropathy. The IL-6 gene was found 
on chromosome 7p21, which contains 
the locus related to reduced glomerular 
filtration rate in type 2 diabetes. They 
examined six representative SNPs in 
the IL-6 gene—five tagging SNPs and 
one previously reported promoter SNP 
(rs1800796; –634G>C)—and showed 
that the haplotype comprising these six 
SNPs was significantly associated with 
impaired renal function but not with 
albumin excretion in patients with type 
2 diabetes. The approach adopted by Ng 
et al.1 is superior to analysis of single 
SNPs; it is considered a good and stand-
ard example of candidate gene analysis 
that completely covers the genes of 
interest. Their finding is consistent with 
a previous finding that microinflamma-
tion is probably involved in the progres-
sion of diabetic nephropathy rather than 
in the onset of the disease. The asso-
ciation of the IL-6 gene with diabetic 
nephropathy has also been examined 
in two other independent studies. Kita-
mura et al. examined the association of 
rs1800796 (–634G>C) with albuminu-
ria,13 and Abrahamian et al. examined 
the association of rs1800795 (–174G>C) 
with albuminuria.14 Because the num-
bers of study subjects in all of these stud-
ies, including that of Ng et al.,1 were not 
large enough to enable the evaluation of 
the true association, the results were not 
conclusive. Furthermore, the mecha-
nism by which the above-mentioned 
haplotype contributes to the suscepti-
bility to impairment of renal function 
has not been elucidated, although some 
functional significance of the SNPs has 
been shown by Fishman et al.15 and 
Kitamura et al.13 Therefore, further 
validation of the association of the IL-6 
gene polymorphisms with the disease 
is required. Several other inflammatory 
cytokine genes, including the IL-1 gene 
cluster on chromosome 2q and tumor 
necrosis factor-α (TNF-α) on chromo-
some 6p21, and chemokines and their 
figure 1 | Microinflammation and diabetic nephropathy. A combination of multiple genetic 
and/or environmental factors is considered to contribute to the pathogenesis of diabetic 
nephropathy. Inflammatory cytokine genes, such as IL-6, might be good candidates for conferring 
susceptibility to diabetic nephropathy. ICAM-1, intercellular adhesion molecule-1; VCAM-1, 
vascular cellular adhesion molecule-1; ROS, reactive oxygen species.
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receptors have also been examined thus 
far. However, even these studies could 
not draw a definite conclusion.
Recent development in the SNP typ-
ing technology and collation of informa-
tion regarding linkage disequilibrium 
in the human genome have facilitated 
GWAS and candidate gene analyses in 
a large number of subjects by using tag-
ging SNPs that can completely cover the 
gene or locus of interest. Because, in the 
case of common genetic variations, the 
genotype-specific differences in bio-
logical functions are expected to be 
very small, an appropriate association 
study such as that conducted by Ng et 
al.1 with a sufficient number of subjects, 
probably several thousand case and con-
trol subjects, should be performed for 
each candidate gene before evaluation 
of the functional significance of genetic 
variations.
Inflammatory cytokine genes might 
be good candidates for genes that confer 
susceptibility to diabetic nephropathy. 
Moreover, well-organized approaches, 
such as GWASs for diabetic nephrop-
athy, are being conducted in several 
independent populations; a conclusion 
regarding the susceptibility genes for 
diabetic nephropathy may be drawn in 
the near future. 
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Gender differences in  
chronic kidney disease
Kunitoshi Iseki1
Women live longer than men. Can this phenomenon be explained by 
chronic kidney disease (CKD)? Gender differences in the prevalence and 
incidence of CKD are discussed.
Kidney International (2008) 74, 415–417. doi:10.1038/ki.2008.261
Women live longer than men. Can this 
phenomenon be explained by chronic 
kidney disease (CKD)? Proteinuria is 
a known risk factor for cardiovascular 
disease (CVD) and mortality. Recently, a 
low estimated glomerular filtration rate 
(eGFR) per se has also become widely 
accepted as a risk factor for CVD and 
mortality.1 The high incidence of infec-
tion and malignancies in the elderly pop-
ulation may be, in part, due to CKD. The 
mortality rate increases with a decline in 
glomerular filtration rate (GFR) and is 
highest among patients with end-stage 
renal disease (ESRD). Therefore, an esti-
mation of GFR is recommended among 
patients with CVD. In such patients, 
serum creatinine should be examined to 
determine the eGFR. The World Health 
Organization now considers kidney dis-
ease a major chronic disease.
CKD is defined as either kidney dam-
age indicated by urine, imaging, and 
histologic findings, or a low eGFR, less 
than 60 ml/min/1.73 m2, for more than 
3 months. GFR is calculated by either the 
Modification of Diet in Renal Disease 
(MDRD) Study equation or the Cock-
croft–Gault formula. The concept of CKD 
was developed to educate physicians and 
the general public in the prevention of 
ESRD and other related medical compli-
cations. The mechanisms underlying the 
increased risk of CVD in CKD patients, 
however, are not well understood. In 
addition to the conventional risk factors 
for CVD, CKD patients often have associ-
ated non-conventional risk factors such as 
volume expansion, sympathetic overactiv-
ity, sleep disturbance, hypoxia, increased 
oxidative stress, dyslipidemia, anemia, 
and serum calcium and phosphate 
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